Back to discover
Disease

Vasculitis

Late-stage therapeutic developmentEmerging research
MeSHVasculitis
1
Publications
21
Clinical trials
7
Associated genes
1
Related proteins
2020
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 5 clinical trials expected to report results, the earliest in Q3 2027.
  • 8 industry developments reported.
Upcoming Milestones
Clinical Milestones6View
Results expected 5
Recently completed 1
Industry & Market8View all 8
+3 more in the activity timeline below
Activity timeline14

Clinical trials

11 sponsors · 0 new · 1 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
21
All trials
6
Active
15
Late-stage
6
Completed
Late-stage studies

A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Phase 4 · Recruiting · Amgen

Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial

Phase 3 · Active, not recruiting · Centre Hospitalier Departemental Vendee

A Multicenter Randomized Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

Salvage Therapy for Patients With Inadequate Response to Standard of Care Therapy in Granulomatosis With Polyangiitis

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

A Phase 3, Open-label, Uncontrolled Single-arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Avacopan in Combination With a Rituximab or a Cyclophosphamide-containing Regimen in Children From 6 Years to < 18 Years of Age With Active ANCA-associated Vasculitis (AAV)

Phase 3 · Active, not recruiting · Amgen

Avacopan With Short-term Reduced-dose Glucocorticoids vs Reduced-dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-associated Vasculitis

Phase 4 · Recruiting · Chiba University
Recruiting

A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Phase 4 · Recruiting · Amgen

A Multicenter Randomized Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

Salvage Therapy for Patients With Inadequate Response to Standard of Care Therapy in Granulomatosis With Polyangiitis

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

Avacopan With Short-term Reduced-dose Glucocorticoids vs Reduced-dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-associated Vasculitis

Phase 4 · Recruiting · Chiba University
Recently completed

Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis: A Prospective, Randomized, Controlled, Double-blind Study

Phase 3 · Completed · Hopital Foch

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine

Phase 3 · Completed · Amgen

An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis

Phase 3 · Completed · Cambridge University Hospitals NHS Foundation Trust

A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis

Phase 3 · Completed · Human Genome Sciences Inc., a GSK Company

Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-life-threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis

Phase 3 · Completed · University Medical Center Groningen

Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides

Phase 2/3 · Completed · Cambridge University Hospitals NHS Foundation Trust

Research activity

1 paper

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Gut Microbiota and Cardiovascular Disease.

Circulation research · 2020 · 756 cites
Recent publications

Gut Microbiota and Cardiovascular Disease.

Circulation research · 2020 · 756 cites
Leading journals1
  • Circulation research1
Leading researchers3
  • Hazen SL1
  • Weeks TL1
  • Witkowski M1
Affiliations (unnormalised)3
  • Center for Microbiome and Human Health (M.W.1
  • Heart and Vascular Institute (S.L.H.)1
  • Lerner Research Institute (M.W.1

Associated genes

7 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

IL50.37CCR10.36NAGPA0.31CPLX10.26XCR10.17SSNA10.01POLR3F0.01

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Interleukin-5via IL50.37

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.

Identifiers
MeSHVasculitis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.